AM-1638 is a potent and orally bioavailable agonist of the GPR40 (FFA1) receptor. It serves as a valuable research tool for investigating the role of this receptor in glucose homeostasis and insulin secretion, with applications in both in vitro and in vivo models of type 2 diabetes.